ReviewAnnals of medicine2025
A review of neuroprotective properties of
Review in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Translational potential of medicinal plants for Alzheimer's disease: integrated evidence from molecular mechanisms to preclinical and clinical findings.Natural products and bioprospecting · 2026Review
- Targeting oxidative stress, senescence, and neurodegeneration: anti-aging perspectives of Urtica dioica and Centella asiatica.Inflammopharmacology · 2026Review
- Centella Asiatica Alleviates Type 2 Diabetes-Related Hepatic Glycolipid Disorders via Regulating UPP1-Mediated Pyrimidine Metabolism.Current issues in molecular biology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDISCUSSION: Evidence shows CA can mitigate oxidative stress, inflammation, mitochondrial dysfunction, and neuronal apoptosis-key mechanisms underlying these conditions. In epilepsy models, asiatic acid suppresses glutamate release, improves synaptic and mitochondrial function, and reduces neuronal damage. In neurodegenerative diseases, CA extracts enhance memory and cognitive functions by activating antioxidant response pathways and protecting hippocampal mitochondria from oxidative stress. CA extracts also display anticonvulsant effects without major toxicity. Against Bisphenol A-induced neurotoxicity, CA alleviates oxidative stress and inflammation while restoring mitochondrial function. For radiation-induced brain injury, CA improves cognition and memory
conclusionsCA demonstrates broad neuroprotective potential, offering multi-target benefits with relatively low toxicity. These findings support its development as a novel therapeutic agent for neurological disorders. Further clinical research is warranted to confirm safety, optimize dosing, and translate preclinical results into effective human treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.